- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Interventions
- IDE196, Binimetinib, Crizotinib
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • Stanford, California + 16 more
- Conditions
- TP53 Y220C Mutation, Advanced Solid Tumors
- Interventions
- metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
- Drug
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide, glyburide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- Interventions
- Ripretinib, Repaglinide
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Miami, Florida • Portland, Oregon
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 102
- States / cities
- Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide, metformin, repaglinide and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 2
- States / cities
- Miami, Florida • Tacoma, Washington
- Conditions
- Healthy Participants
- Interventions
- AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- Midazolam, Repaglinide, TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Type 2 Diabetes
- Interventions
- Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 14
- States / cities
- La Jolla, California • Norwalk, California • Miami, Florida + 10 more
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
- Interventions
- Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 10,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 6
- States / cities
- Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
- Interventions
- Isavuconazole, Repaglinide, Caffeine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Cypress, California • South Miami, Florida • San Antonio, Texas
- Conditions
- Diabetes
- Interventions
- Repaglinide and Insulin
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 12 Years to 20 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Adult Subjects
- Interventions
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide, metformin, repaglinide and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Drug-drug Interaction
- Interventions
- tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Healthy
- Interventions
- LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin
- Drug
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cystic Fibrosis, Diabetes Mellitus
- Interventions
- Insulin Asparte, Repaglinide
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2007
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Springfield, Massachusetts • Minneapolis, Minnesota + 3 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Healthy
- Interventions
- Repaglinide, Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona